Months after exiting clinical hold, Pfizer readies to resume dosing in phase 3 gene therapy trial

Pfizer is finally nearly ready to resume dosing in its phase 3 hemophilia A gene therapy trial. Six months after the FDA lifted the clinical hold on the study, trial sites are set to resume enrollment with a view to restarting dosing in October.